Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma.

Trial Profile

Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Trastuzumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Endometrial cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 21 Aug 2017 Status changed from recruiting to active, no longer recruiting.
    • 20 Aug 2015 Planned End Date changed from 1 Jul 2015 to 1 Jul 2019 as reported by ClinicalTrials.gov.
    • 20 Aug 2015 Planned primary completion date changed from 1 Jul 2015 to 1 Jul 2019 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top